NDA 218171 · Xcovery
Ensacove
Ensartinib Hydrochloride · Oral
NovelCDER novel approval, Dec 18, 2024: To treat non-small cell lung cancer
Last checked: Nov 20, 2026Latest source record: Feb 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 18, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
36
3 Phase 3, 5 recruiting
FAERS reports
45
34 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 17, 2026.
ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )
Mechanism: Ensartinib is a kinase inhibitor of anaplastic lymphoma kinase (ALK) and inhibits other kinases including MET and ROS1. In vitro, ensartinib inhibited phosphorylation of ALK and its downstream signaling proteins AKT, ERK, and S6, thereby blocking ALK-mediated signaling pathways and inhibiting proliferation in cell lines harboring ALK fusions and mutations. In vivo, ensartinib showed anti-tumor activity in a mouse xenograft model of human NSCLC harboring an ALK fusion.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ENSACOVE · ENSARTINIB HYDROCHLORIDE EQ 25MG BASE · CAPSULE, ORAL · Prescription
- ENSACOVE · ENSARTINIB HYDROCHLORIDE EQ 100MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ensartinib" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
Guangdong Association of Clinical TrialsAcademic, hospital or other
NCT03574402 · 400 participants (planned) · Start Jul 9, 2018 · Primary completion Dec 30, 2022
Drug: Avitinib Maleate; Afatinib and 13 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Guangzhou, China
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsPivotal-lookingActive, not recruiting
Xcovery Holdings, Inc.Industry
NCT02767804 · 290 participants · Start Jun 2016 · Primary completion Dec 30, 2025
Drug: X-396 (ensartinib); crizotinib · For: Non-small Cell Lung Cancer
Sites: Tampa, Florida; Athens, Georgia; St Louis, Missouri · 72 sites in all
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsPivotal-lookingNot yet recruiting
The First Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT06955325 · 270 participants (planned) · Start May 2025 · Primary completion Dec 2030
Drug: Icotinib; Rezivertinib and 2 more · For: Non-Small Cell Lung Cancer
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerPivotal-lookingStatus unknown
Betta Pharmaceuticals Co., Ltd.Industry
NCT05341583 · 202 participants (planned) · Start May 24, 2022 · Primary completion Jun 1, 2025
Drug: Ensartinib; Placebo · For: Non-small Cell Lung Cancer
Sites: Tianjin, China
Betta Pharmaceuticals Co., Ltd.Industry
NCT07448116 · 164 participants (planned) · Start Jan 31, 2026 · Primary completion Feb 1, 2029
Drug: MCLA-129; Ensartinib · For: Solid Advanced Tumor
Sites: Beijing, China
- A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Sichuan UniversityAcademic, hospital or other
NCT05186506 · 152 participants (planned) · Start Jan 1, 2022 · Primary completion Dec 15, 2025
Drug: Ensatinib; chemotherapy · For: ALK Fusion Protein Expression; Adjuvant Therapy; Non-Small Cell Lung Cancer
- X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibStatus unknown
Betta Pharmaceuticals Co., Ltd.Industry
NCT03215693 · 152 participants (planned) · Start Sep 28, 2017 · Primary completion Mar 9, 2020
Drug: X-396 capsule · For: Non-Small Cell Lung Cancer
Sites: Beijing, China · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash9
- pruritus7
- constipation6
- drug ineffective5
- fatigue5
- death4
- disease progression4
- oedema4
- adverse event3
- product use issue3
- rash pruritic3
- alanine aminotransferase increased2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 28 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L, Wang Z, Wu G, et al. · JAMA Oncol 2021 · Multicenter Study, Randomized Controlled Trial
- Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Yue D, Huang M, Song P, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Peng TR, Liao PF, Wu TW · Thorac Cancer 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, et al. · Cancer Commun (Lond) 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
Ai X, Wang Q, Cheng Y, et al. · J Thorac Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M, Shao T, Shao H, et al. · BMC Cancer 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Xcovery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.